Abbott Laboratories (ABT) Releases Q4 2025 Earnings: Revenue Miss, EPS Plunges

Abbott Laboratories (ABT) reported fourth-quarter 2025 results. Total revenue was $11.5 billion, up 4.4% year-over-year, while cost of sales was $5.5 billion, up 1.6%.

Gross profit: $11.5 billion (+105.8% YoY)

Operating profit: $11.5 billion (+499.6% YoY)

Net income attributable to common shareholders: $1.8 billion (-80.8% YoY)

Diluted earnings per share: $1.01 (-80.8% YoY)

Cash flow and balance-sheet highlights:

Cash from operating activities: $2.8 billion (-2.8% YoY)

Purchases of property, plant and equipment: $496 million (-31.1% YoY)

Cash and cash equivalents: $7.5 billion (-1.4% YoY)

Total liabilities: $32.9 billion (-1.8% YoY)

Against consensus, revenue of $11.5 billion came below the forecast of $11.9 billion, and diluted EPS of $1.01 trailed the estimate of $1.51.

Key takeaways: modest top-line growth (4.4%) alongside a steep decline in net income and EPS, signaling significant adjustments or non-operating impacts.

Large year-over-year increases in gross and operating profit contrast sharply with the net-income drop, suggesting unusual items affected the bottom line.

Operating cash flow remained solid at $2.8 billion, supported by $7.5 billion in cash and equivalents heading into the new year.

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

Abbott Laboratories Insider Trading Activity

Abbott Laboratories insiders have traded $ABT stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $ABT stock by insiders over the last 6 months:

PHILIP P BOUDREAU (EVP AND CFO) sold 5,550 shares for an estimated $746,758
ERIC SHROFF (Senior Vice President) sold 1,586 shares for an estimated $203,042

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

Abbott Laboratories Hedge Fund Activity

We have seen 1,303 institutional investors add shares of Abbott Laboratories stock to their portfolio, and 1,480 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

JPMORGAN CHASE & CO removed 9,921,282 shares (-25.2%) from their portfolio in Q3 2025, for an estimated $1,328,856,511
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 9,402,356 shares (+112.4%) to their portfolio in Q3 2025, for an estimated $1,259,351,562
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 8,163,796 shares (+64.0%) to their portfolio in Q3 2025, for an estimated $1,093,458,836
PRICE T ROWE ASSOCIATES INC /MD/ added 5,451,244 shares (+52.7%) to their portfolio in Q3 2025, for an estimated $730,139,621
INVESCO LTD. added 4,713,135 shares (+51.0%) to their portfolio in Q3 2025, for an estimated $631,277,301
MORGAN STANLEY added 3,428,144 shares (+9.7%) to their portfolio in Q3 2025, for an estimated $459,165,607
POLEN CAPITAL MANAGEMENT LLC removed 3,248,894 shares (-30.5%) from their portfolio in Q3 2025, for an estimated $435,156,862

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Abbott Laboratories Government Contracts

We have seen $121,309,748 of award payments to $ABT over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

VISN 9 CHEMISTRY AUTOMATION COST PER RESULTS REPORTABLE: $4,757,175
VISN1 BPA FOR IMMUNOCHEMISTRY CPRR TESTING ADDING EQUIPMENT FOR MANCHESTER NH VAMC - WITHIN ORIGINAL SCOPE: $4,335,000
CHEMISTRY IMMUNOASSAY ANALYZER COST PER REPORTABLE RESULT (CPRR) PRICE SCHEDULE UPDATE: $4,000,483
LAB CHEMISTRY SERVICES: $3,766,564
EXERCISING OPTION YEAR 2: $2,600,297

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.

Abbott Laboratories Congressional Stock Trading

Members of Congress have traded $ABT stock 10 times in the past 6 months. Of those trades, 3 have been purchases and 7 have been sales.

Here’s a breakdown of recent trading of $ABT stock by members of Congress over the last 6 months:

REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 1 purchase worth up to $15,000 on 11/18 and 1 sale worth up to $15,000 on 12/19.
REPRESENTATIVE JULIE JOHNSON has traded it 3 times. They made 0 purchases and 3 sales worth up to $45,000 on 12/18, 11/13, 08/14.
REPRESENTATIVE JULIA LETLOW sold up to $15,000 on 12/08.
REPRESENTATIVE BYRON DONALDS has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 12/04.
REPRESENTATIVE RICHARD MCCORMICK purchased up to $15,000 on 11/05.
REPRESENTATIVE RICK LARSEN purchased up to $15,000 on 10/06.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

Abbott Laboratories Analyst Ratings

Wall Street analysts have issued reports on $ABT in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Barclays issued a "Overweight" rating on 01/05/2026
BTIG issued a "Buy" rating on 11/20/2025
RBC Capital issued a "Outperform" rating on 10/16/2025
Wells Fargo issued a "Overweight" rating on 10/16/2025
Raymond James issued a "Outperform" rating on 10/16/2025
Evercore ISI Group issued a "Outperform" rating on 10/16/2025
Benchmark issued a "Buy" rating on 10/10/2025

To track analyst ratings and price targets for Abbott Laboratories, check out Quiver Quantitative's $ABT forecast page.

Abbott Laboratories Price Targets

Multiple analysts have issued price targets for $ABT recently. We have seen 8 analysts offer price targets for $ABT in the last 6 months, with a median target of $146.0.

Here are some recent targets:

Lee Hambright from Bernstein set a target price of $154.0 on 01/09/2026
Matt Miksic from Barclays set a target price of $169.0 on 01/05/2026
Marie Thibault from BTIG set a target price of $145.0 on 11/20/2025
Shagun Singh from RBC Capital set a target price of $147.0 on 10/16/2025
Lawrence Biegelsen from Wells Fargo set a target price of $146.0 on 10/16/2025
Jayson Bedford from Raymond James set a target price of $146.0 on 10/16/2025
Vijay Kumar from Evercore ISI Group set a target price of $142.0 on 10/16/2025